These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


209 related items for PubMed ID: 1341207

  • 21. Potential role of parathyroid hormone as an inhibitor of erythropoiesis in the anemia of renal failure.
    McGonigle RJ, Wallin JD, Husserl F, Deftos LJ, Rice JC, O'Neill WJ, Fisher JW.
    J Lab Clin Med; 1984 Dec; 104(6):1016-26. PubMed ID: 6501997
    [Abstract] [Full Text] [Related]

  • 22. Satisfactory control of secondary hyperparathyroidism with low-calcium dialysate in patients not receiving vitamin D.
    Teruel JL, Nitvarro JF, Marcen R, Aguilera A, Tato A, Ottuño J.
    Miner Electrolyte Metab; 1997 Dec; 23(1):19-24. PubMed ID: 9058365
    [Abstract] [Full Text] [Related]

  • 23. Reversibility of parathyroid gland suppression in CAPD patients with low i-PTH levels.
    Montenegro J, Saracho R, González O, Moina I, Martínez I.
    Clin Nephrol; 1997 Dec; 48(6):359-63. PubMed ID: 9438094
    [Abstract] [Full Text] [Related]

  • 24. CAPD with low calcium dialysate and calcium carbonate: results of a 24-week study.
    Honkanen E, Kala AR, Grönhagen-Riska C, Ikäheimo R.
    Adv Perit Dial; 1992 Dec; 8():356-61. PubMed ID: 1361822
    [Abstract] [Full Text] [Related]

  • 25. Autonomous hyperparathyroidism not associated with increased aluminum absorption.
    Mocan MZ, Mocan H, Fell GS, Junor BJ, Boyce BF.
    Isr J Med Sci; 1992 Jan; 28(1):24-6. PubMed ID: 1733894
    [Abstract] [Full Text] [Related]

  • 26. Calcium alginate, an aluminum-free phosphate binder, in patients on CAPD.
    Passlick J, Wilhelm M, Busch T, Grabensee B, Ohnesorge FK.
    Clin Nephrol; 1989 Aug; 32(2):96-100. PubMed ID: 2766587
    [Abstract] [Full Text] [Related]

  • 27. [Aluminum-balance during haemodialysis (author's transl)].
    Graf H, Stummvoll HK, Kovarik J, Meisinger V, Wolf A, Pinggera WF.
    Wien Klin Wochenschr; 1980 Aug; 92(11):391-4. PubMed ID: 7424016
    [Abstract] [Full Text] [Related]

  • 28. Plasma aluminium: a redundant test for patients on dialysis?
    Gault PM, Allen KR, Newton KE.
    Ann Clin Biochem; 2005 Jan; 42(Pt 1):51-4. PubMed ID: 15802033
    [Abstract] [Full Text] [Related]

  • 29. [The effect of decreasing serum calcium in serum during hemodialysis on PTH levels in children with end stage renal disease].
    Sieniawska M, Ziółkowska H, Pańczyk-Tomaszewska M, Weglarska J.
    Pediatr Pol; 1995 Dec; 70(12):1017-22. PubMed ID: 8649940
    [Abstract] [Full Text] [Related]

  • 30. Comparison of low-dose deferoxamine versus standard-dose deferoxamine for treatment of aluminium overload among haemodialysis patients.
    Kan WC, Chien CC, Wu CC, Su SB, Hwang JC, Wang HY.
    Nephrol Dial Transplant; 2010 May; 25(5):1604-8. PubMed ID: 19948879
    [Abstract] [Full Text] [Related]

  • 31. [Replacement of aluminum-containing phosphate binders by calcium and magnesium carbonates in long-term hemodialysis].
    Zellweger U, Zaugg PY, Dambacher M, Binswanger U, Gautschi K, Hany A.
    Dtsch Med Wochenschr; 1989 Apr 28; 114(17):659-64. PubMed ID: 2707134
    [Abstract] [Full Text] [Related]

  • 32. [Effect on serum aluminium levels of continued ingestion of aluminium gels by patients with chronic renal insufficiency (author's transl)].
    Boukari M, Rottembourg J, Jaudon MC, Clavel JP, Legrain M, Galli A.
    Nouv Presse Med; 1978 Jan 14; 7(2):85-8. PubMed ID: 349501
    [Abstract] [Full Text] [Related]

  • 33. Serum aluminium level in the veneto chronic haemodialysis population: cross-sectional study on 1,026 patients.
    Piccoli A, Andriani M, Mattiello G, Nordio M, Modena F, Dalla Rosa C.
    Nephron; 1989 Jan 14; 51(4):482-90. PubMed ID: 2787000
    [Abstract] [Full Text] [Related]

  • 34. [Aluminum and uremic bone disease. Diagnostic utility of serum aluminum and the deferoxamine (DFO) test ].
    Jarava C, Armas JR, Palma A.
    Nefrologia; 2001 Jan 14; 21(2):174-81. PubMed ID: 11464651
    [Abstract] [Full Text] [Related]

  • 35. Use of the low-dose desferrioxamine test to diagnose and differentiate between patients with aluminium-related bone disease, increased risk for aluminium toxicity, or aluminium overload.
    D'Haese PC, Couttenye MM, Goodman WG, Lemoniatou E, Digenis P, Sotornik I, Fagalde A, Barsoum RS, Lamberts LV, De Broe ME.
    Nephrol Dial Transplant; 1995 Oct 14; 10(10):1874-84. PubMed ID: 8592597
    [Abstract] [Full Text] [Related]

  • 36. [Prolonged and reversible encephalopathy in a chronic haemodialysis patient. Probable responsibility of aluminium salts (author's transl)].
    Buge A, Poisson M, Masson S, Bleibel JM, Lafforgue B, Raymond P, Jaudon MC.
    Nouv Presse Med; 1978 Jun 10; 7(23):2053-9. PubMed ID: 673773
    [Abstract] [Full Text] [Related]

  • 37. Studies of aluminium mobilization in renal dialysis patients using the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one.
    Kontoghiorghes GJ, Barr J, Baillod RA.
    Arzneimittelforschung; 1994 Apr 10; 44(4):522-6. PubMed ID: 8011008
    [Abstract] [Full Text] [Related]

  • 38. Evidence of increased parathyroid activity on discontinuation of high-aluminum dialysate in patients undergoing hemodialysis.
    O'Hare JA, Murnaghan DJ.
    Am J Med; 1984 Aug 10; 77(2):229-32. PubMed ID: 6431809
    [Abstract] [Full Text] [Related]

  • 39. Relationship of predialytic intact parathyroid hormone on secondary hyperparathyroidism in chronic maintenance haemodialysis patients.
    Etoh S, Murata T, Hasegawa Y, Miyahara Y, Ishimura A, Abe Y, Noda R, Ogahara S, Kaneoka H, Saito T.
    Nephrology (Carlton); 2004 Jun 10; 9(3):161-6. PubMed ID: 15189177
    [Abstract] [Full Text] [Related]

  • 40. [Hyperaluminemia in chronic hemodialysis patients. Evaluation of the respective roles of dialysate aluminum and oral aluminum hydroxide].
    Tahiri Y, Moriniere P, Jaudon MC, Dkhissi H, Rosa A, Fournier A.
    Nephrologie; 1983 Jun 10; 4(3):129-33. PubMed ID: 6633778
    [Abstract] [Full Text] [Related]


    Page: [Previous] [Next] [New Search]
    of 11.